GREENVILLE, SC, Nov. 7, 2012 /PRNewswire/ - Scio Diamond Technology Corporation (OTCBB: SCIO) announced today that it has entered into a partnership agreement with Finite Square mBh for the supply of diamond for its specialized ophthalmology and plastic surgery blades and scalpels. Mike McMahon, Scio's COO, says, "Finite Square mBh is an FDA registered, independently owned Southern California Company dedicated exclusively to class 1 and class 2 surgical instruments. A significant key to this partnership is the ability of Scio to adapt its diamond recipes to the needs of Finite Square's unique medical incision applications." Subash Mediratta, Executive Vice President of Finite Square says, "The CVD technology that Scio Diamond brings to the laboratory grown diamond medical application is superior and we feel that the partnership will be beneficial to the Ophthalmology and Plastic Surgeon community worldwide. This will be a first for an American company and the cost benefits to the surgeons and surgery centers will be favorable." "It has always been our intent to supply the medical field with our diamond for innovative applications and precise incision purposes. We are fortunate to now be associated with Finite Square mBh and working hand in hand to develop precision instruments to serve ophthalmologists and the medical field worldwide," says Joseph Lancia, Scio's President and CEO. Scio has completed initial shipments of diamond to Finite Square for trial runs and proto types. About SCIO Diamond Scio Diamond employs a patent-protected chemical vapor deposition process to produce high-quality, single-crystal diamonds in a controlled laboratory setting, with such diamonds referred to as "lab-grown" or cultivated diamonds. The diamonds have the identical chemical, physical and optical properties as diamonds found in the earth, and the company's highly controlled manufacturing process enables it to produce very high-quality, high-purity, high volume, single-crystal colorless, near colorless and fancy colored diamonds.